Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs Revvity Inc (RVTY) Price & Performance

iShares Russell 2000 ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs Revvity Inc — how do they compare? iShares Russell 2000 ETF trades at $293.83, while Revvity Inc trades at $106.58 (market cap $12.29B). The key difference: Revvity Inc pays a 0.25% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, Revvity Inc nearer its low. Which is the better fit depends on your goals.

IWMRVTY
52-Week High
$300.45$117.75
52-Week Low
$214.95$82.26
Market Cap
$12.29B
Sector
Technology
Enterprise Value
$14.78B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM, the iShares Russell 2000 ETF, trades at $292.34, down 0.6% on the day. Technical indicators are mixed with a neutral overall signal, while moving averages show a bullish bias. The ETF has seen strong institutional inflows, with firms like AIA Group and Allspring Global Investments increasing their holdings significantly in Q1 2026 (SEC 13F filings, July 2026). Small-cap stocks have outperformed large-caps year-to-date, with the Russell 2000 up approximately 20% in 2026 (24/7 Wall Street, July 17, 2026).

The outlook for IWM hinges on continued small-cap strength, which is sensitive to interest rates and economic growth. While recent performance is robust, risks include higher volatility versus large-caps and potential Fed policy shifts. Analyst sentiment is divided, with some highlighting valuation concerns versus broader market ETFs.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.

The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY